Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza
Fierce Pharma
OCTOBER 9, 2024
A trial of Biogen’s spinal muscular atrophy therapy Spinraza suggests that a higher dose provides benefits to a broad range of patients.
Wed.Oct 09, 2024
305 
Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs?
MedCity News
OCTOBER 9, 2024
If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California. The post Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? appeared first on MedCity News.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pfizer CEO Bourla to meet with activist investor Starboard Value on turnaround pitch: FT
Fierce Pharma
OCTOBER 9, 2024
With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the company’s executives will reportedly hear out activist investor Starboard Valu | Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives, the Financial Times reported.
Advancing Precision Care For All
pharmaphorum
OCTOBER 9, 2024
Advancing Precision Care For All with Hakim Yadi from Closed Loop Medicine. Listen to the latest podcast episode featuring insights from a leader in the healthcare industry.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Zealand's hypoglycemia drug suffers another FDA rejection tied to CDMO inspection
Fierce Pharma
OCTOBER 9, 2024
After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | Zealand’s glucagon receptor agonist dasiglucagon has been rebuffed by the FDA once again, scrambling the company's plan to launch the hypoglycemia treatment in kids with congenital hyperinsulinism.
Maven Clinic Snags $125M To Boost Fertility Program, Expand Value-Based Care Partnerships
MedCity News
OCTOBER 9, 2024
Maven Clinic’s $125 million Series F funding round was led by StepStone Group and included participation from existing investors General Catalyst, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group and Lux Capital. The post Maven Clinic Snags $125M To Boost Fertility Program, Expand Value-Based Care Partnerships appeared first on MedCity News.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
MedCity FemFwd: Addressing the Maternal Health Crisis with Dr. Bayo Curry-Winchell
MedCity News
OCTOBER 9, 2024
In this episode, we’re joined by Dr. Bayo Curry-Winchell, founder of Beyond Clinical Walls and medical director of urgent care clinics at Saint Mary’s Regional Medical Center. She discusses the role unconscious bias plays in maternal health disparities and ways the healthcare industry can address the maternal health crisis. The post MedCity FemFwd: Addressing the Maternal Health Crisis with Dr.
Leo Pharma unveils up to 250 layoffs and relocations amid CEO's revamp
Fierce Pharma
OCTOBER 9, 2024
Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round of layoffs and relocations. | Leo is closing and relocating up to 250 roles as part of the “next step” in the dermatology company’s evolving strategy, a company spokesperson told Fierce Pharma. Most jobs affected by the move are based in Leo’s home country of Denmark and span “all business areas.
‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response
PharmaVoice
OCTOBER 9, 2024
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's Eylea
Fierce Pharma
OCTOBER 9, 2024
A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected for a variety of common eye diseases, Clearside Biomedical is making sign | Clearside’s CLS-AX (axitinib injectable suspension) has aced a phase 2b trial, achieving its primary and secondary outcomes for patients with neovascular age-related macular degeneration (wet AMD).
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Why HCOs Need a Portfolio Management Approach to AI
MedCity News
OCTOBER 9, 2024
No one AI technology will address everything and solve all problems, so systems should prioritize those that promise the greatest value and ROI. The post Why HCOs Need a Portfolio Management Approach to AI appeared first on MedCity News.
GSK says $2.2bn settlement resolves most Zantac litigation
pharmaphorum
OCTOBER 9, 2024
GSK says a $2.
Look Who’s Talking at HLTH
MedCity News
OCTOBER 9, 2024
HLTH, scheduled for October 20-23 in Las Vegas, spotlights individuals across the healthcare ecosystem from high-powered executives such as the head of health technology at tech and social media giant Meta to Lenny Kravitz, who will talk about health equity. Here’s a preview of who will be speaking at HLTH, what they’ll be talking about, where and when.
Lilly names Thomas Fuchs as its first chief AI officer
pharmaphorum
OCTOBER 9, 2024
Lilly names Thomas Fuchs as its first chief AI officer Phil.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Scholar Rock Scores $300M for Regulatory Filings & Launch Plans for Neuromuscular Disease Drug
MedCity News
OCTOBER 9, 2024
On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. The post Scholar Rock Scores $300M for Regulatory Filings & Launch Plans for Neuromuscular Disease Drug appeared first on MedCity News.
Ex-Pfizer leaders side with firm against activist investor
pharmaphorum
OCTOBER 9, 2024
Ex-Pfizer CEO and finance chief withdraw support for Starboard Value campaign seeking a change in strategy at the pharma group.
What We’re Still Getting Wrong in Cancer Care — Glaring Gaps in the Face of Astonishing Advancements
MedCity News
OCTOBER 9, 2024
Amidst the distress caused by a cancer diagnosis, patients are left to sort through vast amounts of information, treatment options, and concerns around efficacy and side effects, while juggling other life activities. The post What We’re Still Getting Wrong in Cancer Care — Glaring Gaps in the Face of Astonishing Advancements appeared first on MedCity News.
Sage takes another hit as Alzheimer's drug is canned
pharmaphorum
OCTOBER 9, 2024
Sage Therapeutics stops development of dalzanemdor in Alzheimer's, a few months after pulling the plug on the drug in Parkinson's
Could preventative care save the future of the NHS?
Pharmaceutical Technology
OCTOBER 9, 2024
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.
Purespring Therapeutics secures £80 million in Series B funding
PharmaTimes
OCTOBER 9, 2024
New investment to advance gene therapies for kidney diseases
City Therapeutics launches with $135m Series A funding
Pharmaceutical Technology
OCTOBER 9, 2024
City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based medicine.
As AI transforms drug development, biotechs might not need as much Big Pharma support
PharmaVoice
OCTOBER 9, 2024
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
Increase Revenue With Better, Faster Sales Onboarding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
FDA knocks back Zealand's dasiglucagon once again
pharmaphorum
OCTOBER 9, 2024
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.For the second time in less than a year, the FDA has issued a complete response letter to the company citing the need for data on a third-party manufacturing site that had failed an earlier inspection by the agency.
Sanofi launches high-dose flu vaccine in the UK
PharmaTimes
OCTOBER 9, 2024
New vaccine aims to protect older adults from severe flu complications
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Pharmaceutical Technology
OCTOBER 9, 2024
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
CPHI Milan 2024: Fill/Finish and Sustainability
PharmaTech
OCTOBER 9, 2024
Pharmaceutical Technology® Europe sat down with Hanns-Christian Mahler from ten23 health to discuss the fill/finish market and sustainability considerations for facilities.
Benchmarking excellence in IP Operations: a new report by Clarivate
Clarivate
OCTOBER 9, 2024
In recent years, a stream of new technologies, regulations and the pandemic served as a catalyst for creating new operating models. In-house IP departments and law firms quickly adopted home working and embraced digitalization. Now that departments have settled into these new work models, leaders have the time to tactfully readdress industry best practices and ensure their departments are performing as seamlessly as possible.
CPHI Milan 2024: Evolution of Aseptic Processing Equipment for Regulatory Compliance
PharmaTech
OCTOBER 9, 2024
Zaim Gashi, area sales manager of Steriline, discussed the evolution of aseptic processing equipment in line with current regulatory requirements at CPHI Milan.
Eli Lilly appoints Chief AI Officer
European Pharmaceutical Review
OCTOBER 9, 2024
Eli Lilly and Company has appointed Dr Thomas Fuchs as its first Chief AI Officer. He will commence the role on 21 October 2024. Dr Fuchs will direct and lead artificial intelligence (AI) initiatives across different areas the company, including clinical trials and manufacturing, according to Eli Lilly. The new role also involves work to “identify, build and manage AI and machine learning solutions to help Lilly provide medicines to patients around the world”.
Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’
Pharmaceutical Technology
OCTOBER 9, 2024
The company employs machine learning to uncover disease mechanisms at the mRNA level and to identify therapeutic candidates.
Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Let's personalize your content